With Positive Data, Checkpoint Looks to Add Second Indication to BLA

Submitted by admin on June 16, 2022 - 11:11pm

Source:

BioSpace

News Tags:

Checkpoint Therapeutics

FDA

cosibelimab

checkpoint inhibitors

Headline:

With Positive Data, Checkpoint Looks to Add Second Indication to BLA

snippet:

Checkpoint Therapeutics is prepping for a conversation with the U.S. Food and Drug Administration regarding the potential for a second possible indication for its experimental anti-PD-L1 antibody, cosibelimab, based on positive interim efficacy results in a type of carcinoma.

Search form

You are here

With Positive Data, Checkpoint Looks to Add Second Indication to BLA

With Positive Data, Checkpoint Looks to Add Second Indication to BLA